Featured products: Ultimaster™ Sirolimus Eluting Coronary Stent System, Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System
First-in-man angiographic and OCT single arm assessment
Prospective trial at 8 sites in Europe:
Stage: Published and completed
IVUS, intravascular ultrasound; OCT, optical coherence tomography MI, myocardial infarction; MLD, minimal lumen diameter; TLR, target lesion revascularisation; TV, target vessel.Barbato E et al. EuroIntervention 2015;11:541–8.Beleslin B. Presented at EuroPCR 2017, abstract OP0028.
*DAPT duration is counted from the day of the last implanted stent; staging has to be pre-specified at the time of screening and cannot be planned later than
2 months after index PCI. †Patients receiving OAC can stop DAPT 2 months after confirmed randomisation.ASA, acetylsalicylic acid; DAPT, dual antiplatelet therapy; MACCE, major adverse cardiac and cerebral events; MCB, major or clinically relevant non-major bleeding;
MI, myocardial infarction; NACE, net adverse clinical endpoints; OAC, oral anticoagulant therapy; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy.
Terumo. Ultimaster Drug Eluting Stent Instructions for Use, version 0.1-2018; MASTER DAPT trial. Available at https://clinicaltrials.gov/ct2/show/NCT03023020?term=master+dapt&rank=1 (accessed April 2018).
CI, confidence interval.Kaname used as the BMS platform.
Hypothesis: based on estimated Kaname late loss: 0.90±0.50 mm, late loss of 0.40 mm (0.90–0.50 mm) is considered upper limit for
CENTURY study.Barbato E et al. EuroIntervention 2015;11:541–8.
*Mean±SD. Barbato E et al. EuroIntervention 2015;11:541–8;
Barbato E. Presented at EuroPCR 2015, abstract OP047
Ultimaster vs BMS, propensity matched analysis; Kaname used as the BMS platform.*One acute stent thrombosis due to untreated dissection.
CD-TLR, clinically driven target lesion revascularisation; CD-TVR, clinically driven target vessel revascularisation; ST, stent thrombosis.Beleslin B. Presented at EuroPCR 2017, abstract OP0028.
*Composite of cardiac death, target vessel-related MI and CD-TVR.Kaname used as the BMS platform.Beleslin B. Presented at EuroPCR 2017, abstract OP0028.
Barbato E. Presented at EuroPCR 2015, abstract OP047; Barbato E et al. EuroIntervention 2015;11:541–8; Beleslin B. Presented at EuroPCR 2017, abstract OP0028.
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.